Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Soligenix Inc Common (SNGX)  
$0.40 0.00 (0.00%) as of 4:30 Thu 2/9


Download
   
Exchange: OTC Bulletin Board
Security Type: Common
Shares Out: 40,080,000
Market Cap: 16.04(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.4002 - $0.4002
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases. Co.'s business segments are: Specialized BioTherapeutics, which is developing and moving toward potential commercialization of HyBryte™, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma; and Public Health Solutions, which includes development programs for RiVax®, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and other infectious disease and its vaccine programs targeting filoviruses and CiVax™, its vaccine candidate for the prevention of COVID-19.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-02-18 2023-11-17 2023-05-19 2022-05-19

   
Records found: 92
  Page 3 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Lapointe Gregg Anthony Director   –       •      –    2010-06-18 4 B $0.21 $200,000 D/D 975,610 975,610 2.39     -
   Rubin Robert Joseph Director   –       •      –    2010-06-18 4 B $0.21 $50,000 D/D 243,902 243,902 2.39     -
   Cavazza Paolo 10% Owner   –       –       •   2010-06-18 4 B $0.21 $2,364,759 I/I 11,535,409 3,282,929 1.5     -
   Sigma-Tau Pharmaceuticals, Inc. 10% Owner   –       –       •   2010-06-18 4 B $0.21 $1,764,759 I/I 8,608,580 54,227,816 1.5     -
   Biotex Pharma Investments, Llc 10% Owner   –       –       •   2009-10-09 4 D $0.32 $106,195 D/D (335,000) 17,665,000     -
   Biotex Pharma Investments, Llc 10% Owner   –       –       •   2009-10-01 4 D $0.31 $231,525 D/D (750,000) 18,000,000     -
   Biotex Pharma Investments, Llc 10% Owner   –       –       •   2009-09-28 4 D $0.26 $65,500 D/D (250,000) 18,750,000     -
   Schaber Christopher Chief Executive Officer   •       •      –    2009-09-28 4 B $0.25 $20,000 D/D 79,051 471,817 2.81     -
   Cavazza Paolo 10% Owner   –       –       •   2009-09-24 4 B $0.25 $1,000,000 I/I 3,952,569 45,619,236 1.5     -
   Cavazza Claudio 10% Owner   –       –       •   2009-09-24 4 B $0.25 $1,000,000 I/I 3,952,569 45,619,236 1.5     -
   Sigma-Tau Pharmaceuticals, Inc. 10% Owner   –       –       •   2009-09-24 4 B $0.25 $1,000,000 I/I 3,952,569 45,619,236 1.5     -
   Biotex Pharma Investments, Llc 10% Owner   –       –       •   2009-09-18 4 D $0.27 $66,325 D/D (250,000) 18,750,000     -
   Biotex Pharma Investments, Llc 10% Owner   –       –       •   2009-08-11 4 S $0.20 $100,000 D/D (500,000) 19,000,000     -
   Biotex Pharma Investments, Llc 10% Owner   –       –       •   2009-07-30 4 S $0.20 $102,450 D/D (500,000) 19,500,000     -
   Sigma-Tau Pharmaceuticals, Inc. 10% Owner   –       –       •   2009-02-11 4 B $0.18 $4,500,000 I/I 25,000,000 41,666,667 1.5     -
   Cavazza Paolo 10% Owner   –       –       •   2009-02-11 4 B $0.18 $4,500,000 I/I 25,000,000 41,666,667 1.5     -
   Cavazza Claudio 10% Owner   –       –       •   2009-02-11 4 B $0.18 $4,500,000 I/I 25,000,000 41,666,667 1.5     -
   Biotex Pharma Investments, Llc 10% Owner   –       –       •   2009-01-20 3 IO $0.00 $0 D/D 0 20,000,000     -
   Sigma-Tau Pharmaceuticals, Inc. 10% Owner   –       –       •   2008-11-26 3 IO $0.00 $0 I/I 0 16,666,667     -
   Cavazza Claudio 10% Owner   –       –       •   2008-11-26 3 IO $0.00 $0 I/I 0 16,666,667     -
   Cavazza Paolo 10% Owner   –       –       •   2008-11-26 3 IO $0.00 $0 I/I 0 17,022,767     -
   Cavazza Paolo 10% Owner   –       –       •   2008-11-26 3 IO $0.00 $0 D/D 0 1,190,770     -
   Myrianthopoulos Evan Chief Financial Officer   •       •      –    2007-08-29 4 B $0.31 $21,672 D/D 70,000 224,780 2.81     -
   Clavijo James Controller/Treasurer   •       –      –    2007-08-28 4 B $0.30 $10,325 D/D 35,000 88,191 2.74     -
   Schaber Christopher Chief Executive Officer   •       •      –    2007-08-28 4 B $0.29 $29,060 D/D 100,000 392,766 2.81     -
  92 Records found
  1  2  3  4   
  Page 3 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us